EMERGENT BIOSOLUTIONS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
EMERGENT BIOSOLUTIONS INC. (EBS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $300.00K, a 98.09% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $15.70M, a 58.90% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $38.20M, a 620.75% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-08 |
| 2022-12-31 | $300.00K 10-K · filed 2024-03-08 |
| 2021-12-31 | $15.70M 10-K · filed 2024-03-08 |
| 2020-12-31 | $38.20M 10-K/A · filed 2023-12-11 |
| 2019-12-31 | $5.30M 10-K · filed 2022-02-25 |
| 2018-12-31 | $24.40M 10-K · filed 2021-02-19 |
| 2017-12-31 | $13.90M 10-K · filed 2020-02-25 |
| 2012-12-31 | $589.00K 10-K · filed 2013-03-08 |
| 2011-12-31 | $10.20M 10-K · filed 2013-03-08 |
| 2010-12-31 | $7.50M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |